On June 24, Abivax S.A. declined 5.15% in regular trading, trading at $78.42/share, with turnover of $97.69 million.

On the news front, the company's core drug obefazimod faced renewed selling pressure as the unresolved safety controversy surrounding its Phase 3 ABTECT maintenance trial continued to weigh on sentiment. The stock had previously plunged from approximately $130 to around $70 — a nearly 50% decline — after multiple cancer cases emerged in the 50mg dosing group. While some investors argued that the cancer cases were more likely age-related and that the initial market reaction was excessive, driving a technical rebound above $100, the stock has since retreated sharply, indicating that the market remains deeply divided on the safety profile of the drug. The weakening rebound momentum suggests that bulls have been unable to sustain conviction amid persistent uncertainty over the trial's clinical implications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)